Low-dose nivolumab leads to improved overall survival for head and neck cancer patients

Описание к видео Low-dose nivolumab leads to improved overall survival for head and neck cancer patients

Dr Bishal Gyawali speaks to ecancer about the phase 3 randomised study evaluating the addition of low-dose nivolumab to palliative chemotherapy in head and neck cancer.

The study aimed assess whether the addition of low dose nivolumab to MC improved the overall survival of head and neck cancer patients.

In this first-ever randomised study, the addition of low dose nivolumab led to improved overall survival and is an alternative standard of care for those who cannot access full dose nivolumab.

Комментарии

Информация по комментариям в разработке

Похожие видео